PFIZER IS COMMITTED TO HELPING YOU REDUCE THE SERIOUS IMPACT OF SEROGROUP B MENINGOCOCCAL DISEASE (MenB).

WHAT YOU NEED TO KNOW

MenB is an uncommon disease that can kill without warning.^1,2 Quadrivalent meningococcal disease vaccines for serogroups A, C, W, and Y have been available in the United States since 2005, but vaccines for serogroup B have only been available since 2014.^3,4 If you are only vaccinating against A, C, W, and Y (MCV4), your patients may not be protected against the most common serogroups of meningococcal disease.⁵

There are 5 primary serogroups of bacteria in the US that cause the majority of invasive meningococcal disease and for which vaccines are available in the US: A, C, W, Y, and B⁵

60% of all meningococcal disease cases in persons 17 to 23 years of age in the US are caused by serogroup B

Though uncommon, 60% of all meningococcal disease cases in persons 16 to 23 years of age in the US are caused by serogroup B⁶

Almost 1 in 4 adolescents may be asymptomatic carriers
of the bacteria. MenB is unpredictable⁷

Aproximately 1 in 10 MenB cases results in death

Approximately 1 in 10 MenB cases results in death³

Approximately 20% of survivors may be affected by significant long-term or permanent sequelae

Approximately 20% of survivors may be affected by
significant long-term or permanent disabilities such as brain damage, vision loss, and skin scarring⁸

MenB has been responsible for all university outbreaks of meningococcal diseas in the US from 2011 to 2016

MenB has been responsible for all university outbreaks of meningococcal disease in the US from 2011 to 2016⁹^*

^*Until 2014, available vaccines only protected against 4 of the 5 primary serogroups.

STORIES YOU NEED TO HEAR

Hear 3 stories and learn why vaccination is so important.

DR KARLA LOKEN | OB/GYN, SISTER OF LAURA

At the age of 14, Dr Loken lost her sister to MenB, and this tragedy led her to a life of advocating for vaccination.

PATTI WUKOVITS | RN, MOTHER OF VICTIM

As a mother and nurse, Patti had her daughter, Kimberly, vaccinated against meningococcal disease, but did not know that the MCV4 meningococcal vaccine did not help protect against MenB.⁵ When her daughter contracted meningococcal disease there were no vaccines available to help protect against MenB.

GERALD | MENINGOCOCCAL SURVIVOR

Gerald shares his history of how he went from feeling invincible to almost dying.

2017 CDC IMMUNIZATION SCHEDULE HIGHLIGHTS VACCINES FOR 16 YEAR OLDS¹⁰

EVERY EFFORT COUNTS

Educate your office about potentially deadly MenB¹¹

Speak to your patients and parents about the importance of vaccination

Vaccinate all appropriate patients

Discover resources and tools, and learn about a branded vaccine option

More questions? Call your Pfizer Vaccines Specialist at 1-844-439-2571

Developed by Pfizer Inc., in partnership with the Kimberly Coffey Foundation.

References: 1. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated August 10, 2016. Accessed August 12, 2016. 2. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR. 2015;64(22):606-607. 3. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191. 4. Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(22):608-612. 5. McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27(25-26):3417-3421. 6. Centers for Disease Control and Prevention. Meningococcal surveillance. Centers for Disease Control and Prevention website. https://www.cdc.gov/meningococcaI/downloads/NClRD-EMS-Report.pdf. Updated September 15, 2017. 7. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853-861. 8. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-e25. 9. Biswas HH, Han Gs, Wendorf K, et al. Notes from the field: outbreak of serogroup B meningococcal disease at a university—California, 2016. MMWR. 2016;65(20)520-521. 10. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2017. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed February 6, 2017. 11. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 12. Centers for Disease Control and Prevention. Human Papillomavirus (HPV). https://www.cdc.gov/hpv/parents/vaccine.html. Updated August 24, 2017. Accessed October 31, 2017. 13. Centers for Disease Control and Prevention. Influenza (Flu). https://www.cdc.gov/flu/consumer/symptoms.htm. Updated October 27, 2017. Accessed October 31, 2017.